Takeda Pharmaceutical Limited Revenue Growth Rates (TAK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Takeda Pharmaceutical Company Limited  (NYSE: TAK)
 

TAK's Revenue Growth by Quarter and Year

Takeda Pharmaceutical Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TAK Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 29,183.90
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 29,183.90





TAK Revenue fourth quarter 2025 Y/Y Growth Comment
Takeda Pharmaceutical Company Limited reported Revenue growth of 0.06% year on year in the fourth quarter 2025, to $ 29,183.90 millions, this is lower than Takeda Pharmaceutical Company Limited's recent average Revenue growth of 4.53%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Revenue growth. While Takeda Pharmaceutical Company Limited' s Revenue increase of 0.06% ranks overall at the positon no. 1685 in the fourth quarter 2025.


TAK Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 0.06 % 4.53 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   0.06 % 4.53 % - -

Financial Statements
Takeda Pharmaceutical Limited's fourth quarter 2025 Revenue $ 29,183.90 millions TAK's Income Statement
Takeda Pharmaceutical Limited's fourth quarter 2024 Revenue $ 29,166.69 millions Quarterly TAK's Income Statement


TAK Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   0.06 % 4.53 % - -


Back to TAK Growth rate Comparisons >> Back to TAK Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #306
Overall #1685

Revenue Y/Y Growth Statistics
High Average Low
4.53 % 4.53 % 4.53 %
(Mar 31 2024)  
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #306
Overall #1685
Revenue Y/Y Growth Statistics
High Average Low
4.53 % 4.53 % 4.53 %
(Mar 31 2024)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Takeda Pharmaceutical Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TAK's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TAK's IV. Quarter Q/Q Revenue Comment


Takeda Pharmaceutical Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 29,183.90 $ 29,166.69 $ 27,902.33 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 0.06 % 4.53 % - - -
Year on Year Revenue Growth Overall Ranking # 1685 # 1585 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 0.06 % 4.53 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 1685 # 1585 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Takeda Pharmaceutical Limited's cumulative twelve months Revenue were $ 29,184 millions, company would post below average annual Revenue growth of 4.53% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Takeda Pharmaceutical Limited's Revenue growth from the 0% growth in Mar 31 2024.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1585 to 1685.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 306
Overall # 1685

Revenue TTM Y/Y Growth Statistics
High Average Low
4.53 %
 4.53 %
4.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 306
S&P 500 # 1685
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2025 period, Takeda Pharmaceutical Limited's cumulative twelve months Revenue were $ 29,184 millions, company would post below average annual Revenue growth of 4.53% year on year, if the fiscal year would end at Mar 31 2025.
A slow-down in the Takeda Pharmaceutical Limited's Revenue growth from the 0% growth in Mar 31 2024.

In the Healthcare sector 305 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1585 to 1685.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 306
Overall # 1685

Revenue TTM Y/Y Growth Statistics
High Average Low
4.53 %
4.53 %
4.53 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 306
S&P 500 # 1685




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TAK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Takeda Pharmaceutical Company Limited0.06%$ 0.059 millions


About Takeda Pharmaceutical Limited Revenue Growth Rates (TAK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Takeda Pharmaceutical Co Ltd (CIK 1395064).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001395064-26-000177
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Takeda Pharmaceutical Co Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.